Herpes Infections Recently Cost $35 Billion Globally
By Lori Solomon HealthDay Reporter
THURSDAY, July 18, 2024 -- Herpes simplex virus (HSV)-2 and HSV-1 infections and their consequences cost $35 billion globally in 2016, according to a study published online July 2 in BMC Global and Public Health.
Nathorn Chaiyakunapruk, Pharm.D., Ph.D., from the University of Utah in Salt Lake City, and colleagues estimated the global economic impact of genital HSV-2 and HSV-1 infections. Disease burden was based on previously published global disease burden studies in 2016 for 194 countries, while estimates of health care resource utilization were sourced from a literature review and online interviews with 20 experts from all six World Health Organization regions.
The researchers found that genital HSV-2 ($31.2 billion) and HSV-1 ($4.0 billion) infections and their consequences were costly globally. The greatest economic burden emanated from the combined Americas and Western Pacific regions, which accounted for almost two-thirds of the global burden ($20.8 billion). A large proportion of the economic burden was borne by high- and upper middle-income countries (76.6 percent or $27.0 billion). HSV-2 recurrence drove costs.
"HSV prevention interventions have the potential to avert a large economic burden in addition to disease burden; thus, efforts to accelerate HSV vaccine development are crucial," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2024
Read this next
Prior Military Sexual Trauma Linked to Late-Life Suicide Attempt
THURSDAY, May 1, 2025 -- Prior military sexual trauma (MST) is associated with late-life suicide attempt and death by suicide or overdose, according to a study published online...
Antibiotic Noninferior to Ceftriaxone + Azithromycin for Gonorrhea
MONDAY, April 21, 2025 -- For uncomplicated urogenital gonorrhea, gepotidacin, which inhibits bacterial DNA replication, is noninferior to ceftriaxone plus azithromycin, according...
Incidence of Neonatal Herpes Simplex Virus Infections in U.S. 15.7 Per 100,000 Births in 2019
TUESDAY, April 15, 2025 -- The incidence of neonatal herpes simplex virus (nHSV) infections in the United States in 2019 was 15.7 per 100,000 hospital births, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.